Abstract: A vehicle door control system includes a door, holding part, and controller. The door is capable of opening and closing by a motion of swinging relative to a vehicle body. The holding part is capable of switching between an openable-and-closable state and a holding state. The openable-and-closable state is a state in which movement of the door in an opening direction that opens the door and movement of the door in a closing direction that closes the door are allowed. The holding state is a state in which movement of the door in the opening direction is prohibited and movement of the door in the closing direction is allowed. The controller is configured to control the holding part. The controller is configured to set the holding part to the holding state in response to the door stopping its movement while the door is open.

Abstract: A door device includes: a door swingable relative to a vehicle body; an actuator configured to drive the door to open and close; a controller configured to perform drive control on the actuator; and a door open/close detector configured to detect an opening/closing speed of the door, wherein the controller is configured to: determine whether an opening/closing action to be performed on the door is a manual action, in which the door is to be manually opened or closed by a user, or an automatic action, in which the door is to be automatically opened or closed by the actuator; and while the manual action is being performed, learn the opening/closing speed detected by the door open/close detector to generate learned value data including information on the opening/closing speed and to reflect the learned value data to the drive control on the actuator while the automatic action is being performed.

Abstract: A composition containing L-arginine and a glycosyl compound of formula (I): in which R is a moiety formed of a monosaccharide, a disaccharide, or an oligosaccharide including three to five monosaccharides; and the composition contains the glycosyl compound and L-arginine in a molar ratio of 1:1.6 to 1:3.0. Also disclosed is a method for preparing such a composition, as well as a composition prepared by the method.

Abstract: A composition containing L-arginine and a glycosyl compound of formula (I): in which R is a moiety formed of a monosaccharide, a disaccharide, or an oligosaccharide including three to five monosaccharides; and the composition contains the glycosyl compound and L-arginine in a molar ratio of 1:1.6 to 1:3.0. Also disclosed is a method for preparing such a composition, as well as a composition prepared by the method.

Abstract: A water-soluble composition including an O-glycosyl flavonoid compound, L-arginine, a sugar alcohol, and ascorbic acid or an alkali salt of ascorbic acid. The O-glycosyl flavonoid compound is rutin, isoquercitrin, or hesperidin, and a molar ratio between the O-glycosyl flavonoid compound and the sugar alcohol is 1:4.0-12.0. Also provided is a method for making the above-described water-soluble composition by combining the O-glycosyl flavonoid compound, L-arginine, the sugar alcohol, and ascorbic acid or an alkali salt thereof to form a mixture, and heating it at 110° C.-140° C. to melt the mixture.

Abstract: A water-soluble composition including an O-glycosyl flavonoid compound, L-arginine, a sugar alcohol, and ascorbic acid or an alkali salt of ascorbic acid. The O-glycosyl flavonoid compound is rutin, isoquercitrin, or hesperidin, and a molar ratio between the O-glycosyl flavonoid compound and the sugar alcohol is 1:4.0-12.0. Also provided is a method for making the above-described water-soluble composition by combining the O-glycosyl flavonoid compound, L-arginine, the sugar alcohol, and ascorbic acid or an alkali salt thereof to form a mixture, and heating it at 110° C.-140° C. to melt the mixture.

Abstract: A water-soluble composition containing rutin, L-arginine, and an alkali salt of ascorbic acid in which the molar ratio between the rutin, L-arginine, and the alkali salt of ascorbic acid is 1:1.6-3.0:0.1-2.0.

Abstract: A water-soluble pharmaceutical composition containing isoquercitrin, L-arginine, and ascorbic acid or an alkali salt thereof, in which the molar ratio between the isoquercitrin, L-arginine, and the ascorbic acid or alkali salt is 1:1.6-2.6:0.16-1.95.

Abstract: Disclosed is a compound represented by the Structural Formula (I): Y is a covalent bond, a phenylene group or a substituted or unsubstituted straight chained hydrocarbyl group. In addition, Y, taken together with both >C?Z groups to which it is bonded, is a substituted or unsubstituted aromatic group. Preferably, Y is a covalent bond or —C(R7R8)—. R1 and R2 are independently an aryl group or a substituted aryl group, R3 and R4 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R5-R6 are independently —H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R7 and R8 are each independently —H, an aliphatic or substituted aliphatic group, or R7 is —H and R8 is a substituted or unsubstituted aryl group, or, R7 and R8, taken together, are a C2-C6 substituted or unsubstituted alkylene group. Z is ?O or ?S.

Abstract: The invention provides compositions comprising xanthohumol/cyclodextrin complexes that are water soluble and that have increased stability relative to xanthohumol alone.

Abstract: The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein X, Y, A, Z, L and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions and immune disorders.

Abstract: The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein X, Y, A, Z, L and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions and immune disorders.

Abstract: This invention provides fused heterocyclic compounds, pharmaceutical compositions of the compounds, and methods of using the compounds for the treatment of, inter alia, IL-12 related disease and disorders.

Abstract: This invention relates to a composition that contains quercetin, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, vitamin C, caffeine, epigallocatechin gallate, epicatechin, epicatechin gallate, and epigallocatechin.

Abstract: This invention relates to a composition that contains quercetin, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, vitamin C, caffeine, epigallocatechin gallate, epicatechin, epicatechin gallate, and epigallocatechin.

Abstract: Described are 3-hydroxyflavonol compositions with improved water-solubility and methods of making the compositions.

Abstract: This invention features compounds of formula (I): pharmaceutical compositions of the compounds, and methods of using the compounds for the treatment of, inter alia, IL-12-related diseases and disorders.

Abstract: A method for preparing a xanthohumol-rich hop composition. The method includes providing a solution that contains xanthohumol-containing hop substances and effecting precipitation of non-xanthohumol hop substances by adjusting both the salt concentration and pH value of the solution. The xanthohumol-rich hop composition prepared by this method can be used for treating various diseases, e.g., skin disorders, and bacterial infection.

Abstract: This invention relates to a composition that contains quercetin, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, vitamin C, caffeine, epigallocatechin gallate, epicatechin, epicatechin gallate, and epigallocatechin.

Abstract: The present invention features therapeutic and prophylactic compositions comprising xanthohumol and/or xanthohumol/cyclodextrin complexes and methods of using such compositions for treating a skin condition, disease, or disorder.